We are proud to announce that the recent clinical study titled “Uromonitor: Clinical Validation and Performance Assessment of a Urinary Biomarker Within the Surveillance of Patients With Nonmuscle-Invasive Bladder Cancer”, led by Dr. Pedro Ramos et al., has been selected as Editor’s Choice in the March 2025 edition of The Journal of Urology®. This prestigious recognition… Read more »

A recent systematic review and meta-analysis evaluated the performance of Uromonitor®, a urine-based biomarker test for non–muscle-invasive bladder cancer (NMIBC). Analyzing 1,190 tests across four studies, Uromonitor® achieved 80.2% sensitivity, 96.9% specificity, and a high negative predictive value (96.6%). Compared to urinary cytology, Uromonitor® significantly improved sensitivity and test accuracy, reducing unnecessary cystoscopies by up… Read more »

A recent clinical study has confirmed the effectiveness of Uromonitor, an innovative urinary biomarker for the surveillance of nonmuscle-invasive bladder cancer (NMIBC). In a cohort of 439 patients with 528 surveillance episodes, the study demonstrated a sensitivity of 87% and specificity of 99%, along with a negative predictive value of 99%. These results confirm Uromonitor®’s eliability… Read more »

Uromonitor®: Reducing Unnecessary Cystoscopies and TURBT Procedures Non-muscle-invasive bladder cancer (NMIBC) follow-up relies on frequent cystoscopies, which are invasive, costly, and uncomfortable. Uromonitor® is a non-invasive urine test that detects NMIBC recurrence with high accuracy, significantly reducing unnecessary procedures. Fewer Cystoscopies – Uromonitor® could have prevented 87.4% of unnecessary cystoscopies, reducing patient discomfort and healthcare… Read more »

Uromonitor-V2®: A Breakthrough in NMIBC Surveillance Bladder cancer (BCa) requires lifelong monitoring, but traditional methods like cystoscopy and urine cytology are invasive, costly, and often lack sensitivity. Uromonitor-V2® is a non-invasive urine test that detects TERT, FGFR3, and KRAS mutations using real-time qPCR. Clinically validated, it outperforms urine cytology with 93.1% sensitivity and 85.4% specificity,… Read more »

Uromonitor test was recognized and considered by the scientific community as an excellent alternative for the non-invasive follow-up of patients previously diagnosed with Non-Muscle Invasive Bladder Cancer in a scientific article that was issue cover in an recognized international journal (Diagnostics). The details of this study can be found at: https://www.mdpi.com/2075-4418/10/1/39/htm

Concerned about the postponement of surveillance procedures and the increased risk of contamination in Hospitals, a team of researchers from Ipatimup and the Institute for Research and Innovation in Health (i3S) validated a new form of bladder cancer surveillance that, from now on, may be carried-out from home. Bladder cancer mainly affects smoking men over… Read more »

The Uromonitor test was recently validated by the scientific community in a international recognized peer-reviewed journal (Frontiers in Genetics) in a multicentric study comprising more than 300 human samples. Uromonitor presented high sensitivity (74%) and specificity (93%) in the detection of recurrence in patients under Follow-up for Non-Muscle Invasive Bladder Cancer. The details of this… Read more »

Recently, investigators described in a scientific publications in a recognized international journal (International Journal of Molecular Sciences), the future possibility of the use of an genetic alterations in TERT gene, included in the Uromonitor test, to be used as a therapy response predictive biomarker in BCG treatment. The details of this study can be found… Read more »